Biocon Statistics

Total Valuation

Biocon has a market cap or net worth of INR 465.18 billion. The enterprise value is 663.84 billion.

Market Cap	465.18B
Enterprise Value	663.84B

Important Dates

The next estimated earnings date is Wednesday, July 30, 2025.

Earnings Date	Jul 30, 2025
Ex-Dividend Date	Jul 4, 2025

Share Statistics

Current Share Class	1.33B
Shares Outstanding	n/a
Shares Change (YoY)	+0.07%
Shares Change (QoQ)	+0.43%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	445.70M

Valuation Ratios

The trailing PE ratio is 45.91 and the forward PE ratio is 60.19.

PE Ratio	45.91
Forward PE	60.19
PS Ratio	3.05
PB Ratio	1.68
P/TBV Ratio	n/a
P/FCF Ratio	24.17
P/OCF Ratio	11.45
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.55, with an EV/FCF ratio of 34.49.

EV / Earnings	65.51
EV / Sales	4.35
EV / EBITDA	20.55
EV / EBIT	43.02
EV / FCF	34.49

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.66.

Current Ratio	1.14
Quick Ratio	0.71
Debt / Equity	0.66
Debt / EBITDA	5.68
Debt / FCF	9.54
Interest Coverage	1.74

Financial Efficiency

Return on equity (ROE) is 5.40% and return on invested capital (ROIC) is 2.20%.

Return on Equity (ROE)	5.40%
Return on Assets (ROA)	1.68%
Return on Invested Capital (ROIC)	2.20%
Return on Capital Employed (ROCE)	3.47%
Revenue Per Employee	9.35M
Profits Per Employee	621,085
Employee Count	16,315
Asset Turnover	0.27
Inventory Turnover	1.22

Taxes

In the past 12 months, Biocon has paid 4.57 billion in taxes.

Income Tax	4.57B
Effective Tax Rate	24.23%

Stock Price Statistics

The stock price has increased by +6.18% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+6.18%
50-Day Moving Average	333.71
200-Day Moving Average	347.95
Relative Strength Index (RSI)	55.92
Average Volume (20 Days)	156,297

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biocon had revenue of INR 152.62 billion and earned 10.13 billion in profits. Earnings per share was 8.46.

Revenue	152.62B
Gross Profit	92.44B
Operating Income	15.43B
Pretax Income	18.87B
Net Income	10.13B
EBITDA	31.71B
EBIT	15.43B
Earnings Per Share (EPS)	8.46

Full Income Statement

Balance Sheet

The company has 45.65 billion in cash and 183.62 billion in debt, giving a net cash position of -137.97 billion.

Cash & Cash Equivalents	45.65B
Total Debt	183.62B
Net Cash	-137.97B
Net Cash Per Share	n/a
Equity (Book Value)	277.13B
Book Value Per Share	180.66
Working Capital	19.52B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 40.61 billion and capital expenditures -21.37 billion, giving a free cash flow of 19.25 billion.

Operating Cash Flow	40.61B
Capital Expenditures	-21.37B
Free Cash Flow	19.25B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 60.57%, with operating and profit margins of 10.11% and 6.64%.

Gross Margin	60.57%
Operating Margin	10.11%
Pretax Margin	12.36%
Profit Margin	6.64%
EBITDA Margin	20.77%
EBIT Margin	10.11%
FCF Margin	12.61%

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.14%.

Dividend Per Share	0.50
Dividend Yield	0.14%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	5.92%
Buyback Yield	-0.07%
Shareholder Yield	0.07%
Earnings Yield	2.18%
FCF Yield	4.14%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.

Last Split Date	Jun 12, 2019
Split Type	Forward
Split Ratio	2

Scores

Biocon has an Altman Z-Score of 1.63 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.63
Piotroski F-Score	6